Kopran Listed by dragonforce Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

Ransomware groups continue to target organisations across critical sectors, including healthcare and pharmaceuticals, where operational disruption and data exposure can carry significant downstream effects. In this case, the Indian pharmaceutical manufacturer Kopran has been listed by the dragonforce ransomware group, with the group claiming to have exfiltrated internal files during an attack. The listing appeared on 4 April 2026. No information has been released on the number of individuals potentially affected or the precise volume of data involved. Public reporting indicates only that internal files were taken; further technical details, including the method of initial access or the timeline of the intrusion, remain undisclosed.

What happened

Kopran was listed on the leak site associated with the dragonforce ransomware group on 4 April 2026. The group claims to have conducted a ransomware attack that resulted in the exfiltration of internal files. No confirmation of the listing or additional technical details has been provided by Kopran or independent investigators. The number of people affected is not known.

The group behind it: dragonforce

Dragonforce is a ransomware operation that has appeared in public reporting since 2024. Like other groups in this category, it typically gains access through common vectors such as compromised remote-access services or phishing, then deploys encryption while also copying data for leverage. The group maintains a leak site where it lists victims and, in some cases, publishes samples of stolen material when ransom demands are not met. Its listing of Kopran constitutes a claim by the group; independent verification of the underlying incident has not been publicly established.

About Kopran

Kopran Limited and its subsidiary Kopran Research Laboratories Limited operate in the pharmaceutical sector. The company manufactures finished dosage forms and active pharmaceutical ingredients, with more than sixty years of activity in the field. Organisations of this type routinely maintain systems containing research data, manufacturing records, regulatory submissions, and employee information.

What was likely exposed

The only data category named in connection with the listing is internal files exfiltrated during the ransomware attack. The exact contents of those files have not been disclosed. Pharmaceutical manufacturers typically hold proprietary research, production documentation, quality-control records, and administrative data; whether any of these categories were among the files taken in this instance remains unconfirmed.

What's at stake

For individuals whose information appears in internal files, exposure can lead to targeted phishing, identity misuse, or, in the case of employee or research records, reputational or competitive consequences. For the organisation, the incident adds to the operational and regulatory pressures already present in the pharmaceutical supply chain, where data integrity and continuity of manufacturing are closely monitored.

If your data was in this claimed breach

Monitor official statements from Kopran for any further details on the scope of exposure. Enable multi-factor authentication on all accounts that may be linked to the company, and review recent login activity. Individuals can also run a free exposure scan of their email address against known breach datasets to check for prior appearances of their information.

AICompiled with AI assistance from public sources and published under our editorial standards.